Steatosis Is an Independent Predictor of Relapse Following Rapid Virologic Response in Patients With HCV Genotype 3

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 8, 2011, Pages 688-693

  Shah, Samir R ^a   Patel, Keyur ^b   Marcellin, Patrick ^c   Foster, Graham R ^d   Manns, Michael ^e   Kottilil, Shyam ^f   Healey, Letha ^g   Pulkstenis, Erik ^g   Subramanian, G Mani ^g   McHutchison, John G ^b   Sulkowski, Mark S ^h   Zeuzem, Stefan ⁱ   Nelson, David R ^j  

^a BREACH CANDY HOSPITAL   (India)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c BEAUJON HOSPITAL   (France)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g GLAXOSMITHKLINE   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^j UNIVERSITY OF FLORIDA   (United States)

more..

Author keywords

Liver Disease; Prognosis; Recurrence; Response to Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBINTERFERON ALPHA2B; ALPHA INTERFERON; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RAPID VIROLOGIC RESPONSE; RELAPSE; RISK FACTOR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 79960566304     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.04.029     Document Type: Article

References (34)

1. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
2. Hissar S.S., Goyal A., Kumar M., et al. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol 2006, 78:452-458.
3. Lee C.M., Lu S.N., Hung C.H., et al. Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications. Trans R Soc Trop Med Hyg 2006, 100:767-774.
4. Asselah T., Rubbia-Brandt L., Marcellin P., et al. Steatosis in chronic hepatitis C: why does it really matter?. Gut 2006, 55:123-130.
5. Bochud P.Y., Cai T., Overbeck K., et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009, 51:655-666.
6. Adinolfi L.E., Utili R., Andreana A., et al. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci 2001, 46:1677-1683.
7. Zeuzem S., Hultcrantz R., Bourliere M., et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004, 40:993-999.
8. Mangia A., Santoro R., Minerva N., et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005, 352:2609-2617.
9. von Wagner M., Huber M., Berg T., et al. Peginterferon-alpha-2a (40kD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005, 129:522-527.
10. Shiffman M.L., Suter F., Bacon B.R., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007, 357:124-134.
11. Andriulli A., Mangia A., Iacobellis A., et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008, 28:397-404.
12. Aghemo A., Rumi M.G., Soffredini R., et al. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antivir Ther (Lond) 2006, 11:797-802.
13. Jacobson I.M., Brown R.S., Freilich B., et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007, 46:971-981.
14. Mangia A., Dalgard O., Minerva N., et al. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. Aliment Pharmacol Ther 2010, 31:1346-1353.
15. Mangia A. Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients. Liver Int 2011, 31:36-41.
16. Poynard T., Ratziu V., McHutchison J., et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003, 38:75-85.
17. Patton H.M., Patel K., Behling C., et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004, 40:484-490.
18. Rodriguez-Torres M., Govindarajan S., Diago M., et al. Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40kD) (Pegasys) plus ribavirin (Copegus) for 16 or 24 weeks. Liver Int 2009, 29:237-241.
19. Poustchi H., Negro F., Hui J., et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008, 48:28-34.
20. Nelson D.R., Benhamou Y., Chuang W.L., et al. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology 2010, 139:1267-1276.
21. Mangia A., Minerva N., Bacca D., et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009, 49:358-363.
22. Lagging M., Langeland N., Pedersen C., et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008, 47:1837-1845.
23. Dalgard O., Bjøro K., Ring-Larsen H., et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008, 47:35-42.
24. Negro F., Clément S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat 2009, 16:681-688.
25. Rubbia-Brandt L., Quadri R., Abid K., et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000, 33:106-115.
26. Asselah T., Martinot M., Cazals-Hatem D., et al. Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels. J Viral Hepat 2002, 9:29-35.
27. Pazienza V., Clément S., Pugnale P., et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007, 45:1164-1171.
28. Zografos T.A., Liaskos C., Rigopoulou E.I., et al. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am J Gastroenterol 2008, 103:605-614.
29. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
30. Abe H., Ochi H., Maekawa T., et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010, 53:439-443.
31. Li J.H., Lao X.Q., Tillmann H.L., et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010, 51:1904-1911.
32. Mangia A., Thompson A.J., Santoro R., et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010, 139:821-827.
33. Cai T., Dufour J.F., Muellhaupt B., et al. Viral genotype-specific role of PNPLA3, PPARG, MTTP and IL28B in hepatitis C virus-associated steatosis. J Hepatol 2011 Jan 12, [Epub ahead of print].
34. Valenti L., Rumi M., Galmozzi E., et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011, 53:791-799.